Caribou Biosciences (CRBU) Common Equity (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Common Equity of $102.0 million for Q1 2026, down 53.04% year-over-year from $217.2 million in Q1 2025, and down 16.5% quarter-over-quarter from $122.2 million in Q4 2025.
Caribou Biosciences (CRBU) Common Equity (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Common Equity for 7 consecutive years, with $102.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 53.04% year-over-year to $102.0 million; the TTM figure through Mar 2026 stood at $102.0 million (down 53.04% YoY), while the FY2025 annual figure was $122.2 million, down 51.7% from the prior year.
- Common Equity declined to $102.0 million in Q1 2026 per CRBU's latest filing, from $122.2 million in the prior quarter.
- Across five years, Common Equity topped out at $398.3 million in Q3 2023 and bottomed at $102.0 million in Q1 2026.
- Historically, Common Equity has averaged $270.4 million across 5 years, with a median of $281.2 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 1141.77% — and 2026, when it sank 53.04%.
- Caribou Biosciences' Common Equity stood at $300.9 million in 2022, then advanced by 22.44% to $368.4 million in 2023, then tumbled by 31.34% to $253.0 million in 2024, then sank by 51.7% to $122.2 million in 2025, then retreated by 16.5% to $102.0 million in 2026.
- Business Quant data shows CRBU's Common Equity at $102.0 million in Q1 2026, $122.2 million in Q4 2025, and $141.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 98.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.10 Mn |
| Mar 31, 2026 | 102.02 Mn |
| Dec 31, 2025 | 122.18 Mn |
| Sep 30, 2025 | 141.85 Mn |
| Jun 30, 2025 | 166.13 Mn |
| Mar 31, 2025 | 217.22 Mn |
| Dec 31, 2024 | 252.95 Mn |
| Sep 30, 2024 | 281.20 Mn |
| Jun 30, 2024 | 310.46 Mn |
| Mar 31, 2024 | 343.29 Mn |
| Dec 31, 2023 | 368.40 Mn |
| Sep 30, 2023 | 398.27 Mn |
| Jun 30, 2023 | 269.46 Mn |
| Mar 31, 2023 | 278.27 Mn |
| Dec 31, 2022 | 300.87 Mn |
| Sep 30, 2022 | 324.11 Mn |
| Jun 30, 2022 | 347.89 Mn |
| Mar 31, 2022 | 371.80 Mn |
| Dec 31, 2021 | 387.83 Mn |
| Sep 30, 2021 | 404.40 Mn |